Refine your View in Prostate Cancer
B·R·A·H·M·S CgA II KRYPTOR for early identification of treatment-emergent neuroendocrine prostate cancer (NEPC)
Use serum Chromogranin A (CgA) on B·R·A·H·M·S KRYPTOR instruments as a tool in early detection of prostate cancer transition during monitoring of all your patients under hormonal therapy. The fully automated immunoassay for Chromogranin A is not only indicated in neuroendocrine tumors but also provides a tool to early identify neuroendocrine differentiated prostate cancer and ADT resistance.
Find out below how our product can help you in the clinical care of your patients or contact us directly.
CgA in prostate cancer – Videos
More information on B·R·A·H·M·S CgA ll KRYPTOR in prostate cancer
- EN: Literature Review and study overview. Chromogranin A for therapy monitoring of patients with prostate cancer
Bray, F., et al., CA Cancer J Clin, 2018. 68(6): p. 394–424.
Beltran, H., et al., Cancer Discov, 2011. 1(6): p. 487–95.
Tritschler, S., et al., Pathologe, 2018. 39(4): p. 333–343.
Tarle, M., M.Z. Ahel, and K. Kovacic, Anticancer Res, 2002. 22(4): p. 2525–9.
Berruti, A., et al., J Urol, 2007. 178(3 Pt 1): p. 838-43; quiz 1129.
Aggarwal, R.R., F.Y. Feng, and E.J. Small, Oncology (Williston Park), 2017. 31(6): p. 467–74.
Hirano, D., et al., Scand J Urol Nephrol, 2007. 41(4): p. 297–301.2.
Sciarra, A., et al., Urol Int, 2009. 82(2): p. 147– 51.